Moberg Pharma AB Year-end report 2016
EBITDA TRIPLED IN THE FOURTH QUARTERPERIOD (FULL YEAR 2016) * · Net sales SEK 334.3 million (285.6) · EBITDA SEK 77.9 million (46.4) · EBITDA for Commercial Operations SEK 93.5 million (68.5) · Earnings before interest and taxes (EBIT) SEK 62.2 million (35.2) · Net profit after tax SEK 32.7 million (25.5) · Earnings per share SEK 2.25 (1.77) · Operating cash flow per share SEK -1.24 (2.12) · The Board of Directors proposes that no dividend be paid for the 2016 financial year FOURTH QUARTER (OCT-DEC 2016) · Net sales SEK 89.4 million (53.7) · EBITDA SEK